What It Is
Vesugen is a short synthetic tripeptide made of lysine, glutamic acid, and aspartic acid, in that order — written as Lys-Glu-Asp or abbreviated KED, and referenced in older Russian-language literature as "Vezugen."[1] It is catalogued under CAS 204271-66-9, molecular weight roughly 390 g/mol.
Like other short peptide "bioregulators" from the same research tradition, Vesugen is studied mainly for effects on vascular and endothelial cell signaling. It is sold in Western markets exclusively as a research-use-only chemical; vendor pages typically state it is not a drug, has not been evaluated by the FDA, and is not intended for human or animal use.[2]
How It Works
Vesugen's proposed mechanism is gene-regulatory rather than receptor-based in the conventional sense. In vitro studies report that it increases expression of Ki-67, a standard marker of active cell division, in cultured vascular tissue, and molecular-docking models suggest the peptide could interact with a promoter region of the MKI67 gene — essentially proposing that this small peptide enters cells and influences a gene's activity directly.[3]
Separate in vitro work reports that Vesugen normalizes endothelin-1 — a vessel-constricting signal elevated in atherosclerosis models — and increases SIRT1, a protein often discussed in aging biology.[4] These are coherent lab observations, but they fall well short of showing the peptide reaches, and acts on, these targets inside a living person.
What the Research Shows
Nearly all mechanistic evidence for Vesugen comes from cell and tissue-culture work — vascular, lymphocyte, and neuronal culture models — rather than clinical trials.[5] The one notable human-adjacent data point is a small study, reportedly involving around 41 patients, describing improved penile arterial blood flow after treatment with the peptide (there called "Vezugen") for vasculogenic erectile dysfunction linked to atherosclerosis.[6] That is a modest, older, non-Western study that does not meet contemporary cardiovascular research standards.
Additional promotional material describes Vesugen as the active ingredient in an oral supplement, with dosing schemes presented in marketing terms rather than derived from controlled trials. The human evidence overall is thin, geographically narrow, and not comparable to mainstream vascular therapies.
Safety & Side Effects
Public safety information on Vesugen is limited. Some vendor materials describe it as generally well tolerated in the studies they reference, with occasional mild injection-site irritation noted informally, but this is far short of a systematic safety trial.
Because part of its proposed mechanism involves stimulating a cell-proliferation marker, there are legitimate open questions about long-term safety; increased proliferation signaling is not automatically benign once removed from a controlled experiment. Broader reporting on the unapproved-peptide market has also flagged contamination, mislabeling, and inconsistent purity for peptides sold online — risks that apply to Vesugen as much as to any other unregulated product.[7]
Regulatory Status
Vesugen has no FDA approval, and the sources reviewed show no validated regulatory approval in any other country; it is uniformly marketed as a research chemical.[2] Any claim of overseas medical use or approval should be treated skeptically absent verifiable documentation, since the supporting literature is mainly older non-Western journal articles, a translated academic paper, and commercial brochures rather than filings with a recognized drug regulator.
Identity & Purity Verification
Short tripeptides like Vesugen are easy to mislabel or confuse with similar-sounding compounds. Some listings advertised as "Vesugen" have shown an entirely different sequence — EDR instead of KED — alongside a different CAS number and molecular weight, meaning a buyer relying on that listing would not actually get the peptide the research describes.[8]
Anyone evaluating Vesugen claims should check that sequence, CAS number, and molecular weight are internally consistent, and treat a missing or inconsistent certificate of analysis — one lacking HPLC/MS identity data — as a reason for caution, since identity confusion undermines any conclusion drawn from the research.